Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
Cardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease. Sacubitril/valsartan is a new drug combination that has been...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.892460/full |
| _version_ | 1818490301273079808 |
|---|---|
| author | Nor Hidayah Mustafa Juriyati Jalil Satirah Zainalabidin Mohammed S.M. Saleh Ahmad Yusof Asmadi Yusof Kamisah |
| author_facet | Nor Hidayah Mustafa Juriyati Jalil Satirah Zainalabidin Mohammed S.M. Saleh Ahmad Yusof Asmadi Yusof Kamisah |
| author_sort | Nor Hidayah Mustafa |
| collection | DOAJ |
| description | Cardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease. Sacubitril/valsartan is a new drug combination that has been approved for patients with heart failure. This review aims to detail the mechanism of action for sacubitril/valsartan in cardiac remodeling, a cellular and molecular process that occurs during the development of heart failure. Accumulating evidence has unveiled the cardioprotective effects of sacubitril/valsartan on cellular and molecular modulation in cardiac remodeling, with recent large-scale randomized clinical trials confirming its supremacy over other traditional heart failure treatments. However, its molecular mechanism of action in cardiac remodeling remains obscure. Therefore, comprehending the molecular mechanism of action of sacubitril/valsartan could help future research to study the drug’s potential therapy to reduce the severity of heart failure. |
| first_indexed | 2024-12-10T17:15:03Z |
| format | Article |
| id | doaj.art-8ea3b9142c3b45bf97b0efd2042ee269 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-10T17:15:03Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-8ea3b9142c3b45bf97b0efd2042ee2692022-12-22T01:40:10ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.892460892460Molecular mechanisms of sacubitril/valsartan in cardiac remodelingNor Hidayah Mustafa0Juriyati Jalil1Satirah Zainalabidin2Mohammed S.M. Saleh3Ahmad Yusof Asmadi4Yusof Kamisah5Centre for Drug and Herbal Research Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaCentre for Drug and Herbal Research Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaProgram of Biomedical Science, Centre of Applied and Health Sciences, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaDepartment of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaUnit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia, Kuala Lumpur, MalaysiaDepartment of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaCardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease. Sacubitril/valsartan is a new drug combination that has been approved for patients with heart failure. This review aims to detail the mechanism of action for sacubitril/valsartan in cardiac remodeling, a cellular and molecular process that occurs during the development of heart failure. Accumulating evidence has unveiled the cardioprotective effects of sacubitril/valsartan on cellular and molecular modulation in cardiac remodeling, with recent large-scale randomized clinical trials confirming its supremacy over other traditional heart failure treatments. However, its molecular mechanism of action in cardiac remodeling remains obscure. Therefore, comprehending the molecular mechanism of action of sacubitril/valsartan could help future research to study the drug’s potential therapy to reduce the severity of heart failure.https://www.frontiersin.org/articles/10.3389/fphar.2022.892460/fullsacubitrilvalsartanLCZ696neprilysin inhibitorfibrosiscardiac function |
| spellingShingle | Nor Hidayah Mustafa Juriyati Jalil Satirah Zainalabidin Mohammed S.M. Saleh Ahmad Yusof Asmadi Yusof Kamisah Molecular mechanisms of sacubitril/valsartan in cardiac remodeling Frontiers in Pharmacology sacubitril valsartan LCZ696 neprilysin inhibitor fibrosis cardiac function |
| title | Molecular mechanisms of sacubitril/valsartan in cardiac remodeling |
| title_full | Molecular mechanisms of sacubitril/valsartan in cardiac remodeling |
| title_fullStr | Molecular mechanisms of sacubitril/valsartan in cardiac remodeling |
| title_full_unstemmed | Molecular mechanisms of sacubitril/valsartan in cardiac remodeling |
| title_short | Molecular mechanisms of sacubitril/valsartan in cardiac remodeling |
| title_sort | molecular mechanisms of sacubitril valsartan in cardiac remodeling |
| topic | sacubitril valsartan LCZ696 neprilysin inhibitor fibrosis cardiac function |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.892460/full |
| work_keys_str_mv | AT norhidayahmustafa molecularmechanismsofsacubitrilvalsartanincardiacremodeling AT juriyatijalil molecularmechanismsofsacubitrilvalsartanincardiacremodeling AT satirahzainalabidin molecularmechanismsofsacubitrilvalsartanincardiacremodeling AT mohammedsmsaleh molecularmechanismsofsacubitrilvalsartanincardiacremodeling AT ahmadyusofasmadi molecularmechanismsofsacubitrilvalsartanincardiacremodeling AT yusofkamisah molecularmechanismsofsacubitrilvalsartanincardiacremodeling |